AF.50 SAFETY AND CLINICAL EFFICACY OF THE DOUBLE SWITCH FROM ORIGINATOR INFLIXIMAB TO BIOSIMILARS CT-P13 AND SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (SCESICS): A MULTICENTER COHORT STUDY. (September 2021) - Mazza, S.; Piazza O Sed, N.; Conforti, F.S.; Fascì, A.; Casini, V.; Ricci, C.; Munari, F.; Pirola, L.; Invernizzi, P.; Girelli, C.; Lupinacci, G.; Pastorelli, L.; et al.